Ovarian Cancer

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Mirvetuximab soravtansine was found to produce clinically meaningful antitumor activity with acceptable safety and tolerability in patients with platinum-resistant ovarian cancer and high folate receptor–alpha (FRα) expression.

The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy.

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.

Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.

Intravenous chemotherapy plus bevacizumab did not demonstrate differences in progression-free and overall survival compared with intraperitoneal chemotherapy plus bevacizumab in patients with advanced ovarian cancer with no macroscopic disease.

Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.

Maintenance therapy with olaparib will be examined in patients with BRCA1/2 wild-type advanced ovarian cancer who responded to first-line, platinum-based chemotherapy in the phase 3 MONO-OLA1 trial.

Oregovomab, an investigational monoclonal antibody with promising phase 2 data, is being tested in combination with paclitaxel for patients with advanced epithelial ovarian cancer in the phase 3 FLORA-5 trial.

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Alexander Babatunde Olawaiye, MD, discusses frontline and second-line maintenance in ovarian cancer, the role of surgery in platinum-sensitive disease, and updates in cervical and endometrial cancers.

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

The MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared with current standard-of-care therapies in patients with relapsed or persistent low-grade serous ovarian carcinoma, making it the potential new SOC for this patient population.

Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and management strategies for common adverse effects associated with these therapies.

The combination of ixabepilone and bevacizumab significantly improved progression-free survival vs ixabepilone alone in the treatment of platinum-resistant ovarian cancer, according to data from the phase 2 trial published in the British Journal of Cancer.

Kathleen Moore, MD, discusses current standard of care in treating ovarian cancer.

The Data Safety Monitoring Board for the ongoing phase 1/2 OVATION 2 trial has unanimously recommended that patients continue to receive treatment with the novel gene-mediated immunotherapy, GEN-1, at a dose of 100 mg/m2.

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

Oncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.

Robert W. Holloway, MD, and Chad A. Hamilton, MD, provide clinical pearls for community physicians using maintenance therapies for ovarian cancer.

Key opinion leaders discuss how they decide between two regimens for ovarian cancer maintenance therapies.

Experts review the potential maintenance therapy approaches for a 64-year-old woman with stage IIIC high-grade serous ovarian cancer.

Dr. Chad Hamilton explains pivotal data from several important clinical trials in ovarian cancer.